AnaCardio appoints Elin Rosendahl as CDO

PRESS RELEASE
Stockholm, Sweden, April 3, 2024

AnaCardio AB announces today the appointment of Elin Rosendahl, MSc as Chief Development Officer (CDO). Elin has more than 20 years of experience in managing global biopharmaceutical development programs and leading global cross-functional teams in both small and large pharma companies, and joins AnaCardio from her previous role as Vice President, Clinical Development at Vicore Pharma AB.

“I am pleased to welcome Elin to our growing AnaCardio team. Her extensive leadership skills and profound knowledge in clinical development will be a great asset for AnaCardio and the AC01 program going forward.”, commented Patrik Strömberg, CEO.

Elin Rosendahl said: "I am very excited to join the AnaCardio team in this important phase of development. The lead development program, AC01, explores a novel and unique mode of action with the potential to transform the treatment of patients with heart failure”.

For further information, please contact
Patrik Strömberg, CEO
Telephone: +46 704 156 159
E-mail: Patrik.stromberg@anacardio.com

About AnaCardio
AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. Its lead program AC01 is an oral ghrelin peptidomimetic small-molecule is being developed as a contractile agent in heart failure patients.
You can find more information about AnaCardio at www.anacardio.com.